Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Anti-aging pill tested to boost seniors' stamina

NCT ID NCT07144527

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a supplement called nicotinamide mononucleotide (NMN) can improve exercise tolerance in healthy adults aged 60 to 80. Participants will take either the supplement or a placebo and measure how long they can cycle before getting tired. The goal is to see if NMN can help older adults stay active and fit.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Nicotinamide mononucleotide (NMN) supplement
What this could lead to
If it works, this could point toward a simple supplement to help older adults stay active and exercise longer.
What could go wrong
This is a small, early-stage trial with only 40 participants. The supplement may not improve exercise tolerance, and results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 60 to 80 years, of any sex * Written clearance from primary care physician confirming medical fitness to participate in an exercise-based clinical study * Normal or near-normal cardiovascular function to safely engage in moderate to vigorous exercise, demonstrated by either: stress echocardiogram or coronary CT angiogram within the past 12 months showing normal left ventricular function, no significant valvular heart disease, no ischemic changes, and no other clinically significant abnormalities, plus confirmation that no new cardiovascular symptoms (e.g., chest pain, dyspnea, syncope) or changes in health status have occurred since testing * Montreal Cognitive Assessment (MoCA) score of 26 or higher * Free from acute or uncontrolled chronic medical conditions that would pose a risk or interfere with study participation * Physically capable of engaging in structured exercise involving moderate to vigorous intensity stationary cycling * Successful completion of a graded exercise test (e.g., stationary bike) without significant adverse events or contraindications * Ability to attend at least four in-person laboratory visits in Beverly Hills, California * Non-smoker for at least 12 months * Able to provide informed consent and comply with study procedures * Willing to refrain from initiating new exercise, dietary supplement, or medication regimens during the study Exclusion Criteria: * Severe cardiovascular disease (e.g., recent myocardial infarction \<6 months, unstable angina, uncontrolled hypertension \>160/100 mmHg) * Severe respiratory conditions (e.g., advanced COPD or other conditions preventing exercise participation) * Significant neurological impairments that hinder comprehension of instructions or participation in exercise * Terminal illness or conditions limiting life expectancy or ability to complete the study * Severe cognitive impairment preventing informed consent, protocol adherence, or comprehension of interventions * Significant orthopedic limitations or injuries that prevent safe exercise participation * Use of NMN, NR, or other NAD+-altering supplements within the past 14 weeks * Anticipated or current alcohol consumption \>2 drinks per week, or unwillingness to abstain from alcohol during the study * Current substance abuse affecting study participation or adherence * Other acute or chronic health conditions judged by the investigators to pose risk or interfere with study objectives * Non-compliance with study requirements, withdrawal of informed consent, or unforeseen circumstances compromising completion * Any condition which, in the opinion of the investigator, would interfere with study participation or interpretation of results

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aging are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Frailty

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Medical Office of Dr. Robert Huizenga MD

    RECRUITING

    Beverly Hills, California, 90210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.